Drugs / modified CEA peptide
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT00203892 | Apr 2003 → Jun 2009 | pancreatic adenocarcinoma | University of Chicago | Completed | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | modified CEA peptide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00203892 ↗ |
| Known as | mCEA | “The purpose of this study is to determine whether the experimental vaccine "modified CEA peptide CAP 1 -6D" (mCEA) can produce an immune response in patients with pancreatic...” NCT00203892 ↗ |
| Modality | Peptide | “CAP1-6D, an altered peptide ligand can help bypass tolerance.” PMID 24829746 ↗ Jun 2013 |